ClearPoint Neuro Inc, a global medical technology company specializing in device, cell, and gene therapy solutions for precise brain and spine navigation, has announced the acquisition of San Diego-based IRRAS Holdings Inc. IRRAS focuses on neurocritical care, particularly in treating intracerebral hemorrhage, chronic subdural hematoma, and other conditions involving intracranial fluid management.

At the core of IRRAS’s portfolio is the IRRAflow system — a US FDA-cleared and CE-marked technology that integrates continuous irrigation, aspiration, and real-time intracranial pressure monitoring. The system also allows for the delivery of physician-directed fluids and shows potential for targeted intracranial drug delivery, with clinical literature citing investigational use in administering antibiotics and antithrombotic agents.

The acquisition adds over 50 active customers and 10 new patent families to ClearPoint Neuro’s portfolio. The IRRAflow system has been featured in more than 30 peer-reviewed studies demonstrating clinical benefits such as reduced catheter occlusions, lower infection risk, and shorter treatment times — potentially reducing hospital costs.

ClearPoint Neuro expects the acquisition to accelerate its neuro drug delivery portfolio and immediately expand commercial reach across an estimated USD 0.5 billion intracranial bleeding treatment market. CEO Joe Burnett described the merger as a strategic step toward establishing ClearPoint Neuro as a “one-stop shop” for cell, gene, and therapy delivery in neurosurgery and biopharma.

IRRAS CEO Will Martin emphasized the company’s rapid growth and readiness to scale with ClearPoint Neuro, citing an 83 percent rise in 2025 revenues to an estimated USD 9 million annual run-rate. The combined company projects total 2026 revenue between USD 54 million and USD 60 million, with further integration expected to unlock additional growth opportunities in neurocritical and drug delivery care.